1 March 2023 - Currently available evidence is rated as promising but inconclusive to determine whether lecanemab provides a net health benefit over supportive care; the evidence suggests drug would achieve common thresholds for cost effectiveness if priced between $8,900-$21,500/year.

The ICER today posted its revised evidence report assessing the comparative clinical effectiveness and value of the emerging treatment lecanemab (Leqembi, Eisai) for Alzheimer’s disease.

Read ICER Announcement